Coley Phase II NSCLC data

Coley (Wellesley, Mass.) said in an open-label Phase II trial in 48 evaluable patients with non-small cell lung cancer (NSCLC), 13 of 31 patients receiving its ProMune ( CP 7909) plus chemotherapy had...